# Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

> **NCT06749730** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Unresectable Biliary Tract Carcinoma

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Apatinib
- **DRUG:** gemcitabine and cisplatin

## Key facts

- **NCT ID:** NCT06749730
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06749730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06749730, "Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06749730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*